

# 1 Finger stick blood test to assess post vaccination SARS-CoV-2 2 neutralizing antibody response against variants

3  
4 Sing Mei Lim<sup>1,†</sup>, Hoi Lok Cheng<sup>1,†</sup> Huan Jia<sup>1,†</sup>, Patthara Kongsuphol<sup>1,†,‡</sup>, Bhuvaneshwari  
5 D/O Shunmuganathan<sup>2</sup>, Ming Wei Chen<sup>3</sup>, Say Yong Ng<sup>1</sup>, Xiaohong Gao<sup>3</sup>, Shuvan Prashant  
6 Turaga<sup>4</sup>, Sascha P. Heussler<sup>4</sup>, Joyti Somani<sup>5</sup>, Sharmila Sengupta<sup>5</sup>, Dousabel MY Tay<sup>6</sup>,  
7 Megan E. McBee<sup>1</sup>, Barnaby E. Young<sup>7,8,9</sup>, Paul A. MacAry<sup>2,10</sup>, Hadley D. Sikes<sup>1,6,\*</sup>, Peter R.  
8 Preiser<sup>1,6,\*</sup>

## 9 10 **Authors' Affiliations:**

11 <sup>1</sup> Antimicrobial Resistance Interdisciplinary Research Group (AMR-IRG), Singapore-MIT  
12 Alliance in Research and Technology (SMART); #03-10/11 Innovation Wing, 1 CREATE  
13 Way, Singapore 138602.

14  
15 <sup>2</sup> Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National  
16 University of Singapore (NUS); 5 Science Drive 2, Blk MD4, Level 3, Singapore 117545.

17  
18 <sup>3</sup> School of Biological Sciences (SBS), Nanyang Technological University (NTU); 60  
19 Nanyang Dr, Singapore 637551.

20  
21 <sup>4</sup> Attonics System Pte. Ltd. 10 Anson Road, #12-01 International Plaza, Singapore 079903.

22  
23 <sup>5</sup> National University Hospital (NUH); 5 Lower Kent Ridge Rd, Singapore 119074.

24  
25 <sup>6</sup> Department of Chemical Engineering, Massachusetts Institute of Technology (MIT); 25  
26 Ames Street, Building 66 Cambridge, MA 02139, USA.

27  
28 <sup>7</sup> National Centre for Infectious Diseases (NCID); 16 Jalan Tan Tock Seng, Singapore  
29 308442.

30  
31 <sup>8</sup> Department of Infectious Diseases, Tan Tock Seng Hospital; 16 Jalan Tan Tock Seng,  
32 Singapore 308442.

33  
34 <sup>9</sup> Lee Kong Chian School of Medicine; 59 Nanyang Drive Singapore 636921.

35  
36 <sup>10</sup> Life Sciences Institute (LSI), National University of Singapore (NUS); #05-02, 28 Medical  
37 Drive, Singapore 117456.

38  
39  
40  
41  
42  
43 † SM, HC, HJ and PK contribute equally as co-first authors.

44 ‡ PK current affiliation is Thrixen Pte. Ltd.

45 \* HDS and PRP are co-corresponding authors. Emails: [sikes@mit.edu](mailto:sikes@mit.edu);

46 [prpreiser@ntu.edu.sg](mailto:prpreiser@ntu.edu.sg).

47  
48 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

49 **ABSTRACT**

50 There is clinical need for a quantifiable point-of-care (PoC) SARS-CoV-2 neutralizing  
51 antibody (nAb) test that is adaptable with the pandemic's changing landscape. Here,  
52 we present a rapid and semi-quantitative nAb test that uses finger stick or venous  
53 blood to assess the nAb response of vaccinated population against wild-type, alpha,  
54 beta, gamma, and delta variant receptor binding domains. It captures a clinically  
55 relevant range of nAb levels, and effectively differentiates pre-vaccination, post 1<sup>st</sup>  
56 dose and post 2<sup>nd</sup> dose vaccination samples within 10 minutes. The data observed  
57 against alpha, beta, gamma, and delta variants agrees with published results  
58 evaluated in established serology tests. Finally, our test revealed a substantial  
59 reduction in nAb level for beta, gamma, and delta variants between early BNT162b2  
60 vaccination group (within 3 months) and later vaccination group (post 3 months). This  
61 test is highly suited for PoC settings and provides an insightful nAb response in a post-  
62 vaccinated population.

63

64 **KEYWORDS**

65 SARS-CoV-2; COVID19; neutralizing antibody; serology test; cellulose-pulldown  
66 assay; point-of-care test; humoral response against COVID19 variants.

67

## 68 **1 INTRODUCTION**

69 Highly transmissible SARS-CoV-2 variants such as B.1.1.7 (alpha) and B.1.617.2  
70 (delta) have emerged and displaced the 'wildtype' virus and other variants within  
71 countries with high vaccination rates. With 38.9 % of global population now vaccinated  
72 (as of 5th Nov 2021, live update from <https://ourworldindata.org/covid-vaccinations>),  
73 reports of breakthrough infections among vaccinees indicate the potential need for  
74 future vaccine boosters, particularly in vulnerable populations <sup>1-3</sup>. A rapid, easy to use  
75 Point-of-Care (PoC) test that measures the level of immune protection against SARS-  
76 CoV-2 in both recovered as well as vaccinated individuals over time would be an  
77 important tool in guiding public health policy. Currently, standard viral neutralization  
78 test (VNT) and pseudovirus neutralization test (pVNT) have played critical roles in  
79 evaluating protective immunity, however their use is limited due to the need for BSL2  
80 or BSL3 laboratory facilities, extended experimental time and relevant expertise.  
81 Moreover, the reproducibility varies depending on cell type, virus/pseudovirus  
82 generation, experimental protocol, and detection method <sup>4,5</sup>. While ELISA-based  
83 surrogate neutralization test can provide reliable information on immune protection, it  
84 requires skilled operators and dedicated facilities that are difficult to integrate into PoC  
85 testing <sup>6,7</sup>. PoC lateral flow tests are currently limited, as they either detect total  
86 immunoglobulin level which is not a reliable indicator for immune protection or only  
87 provide qualitative assessment <sup>8,9</sup>. The availability of a quick and accurate PoC nAb  
88 test to track vaccination induced immune responses especially against variants at both  
89 the population as well as individual level would be a valuable tool in enabling public  
90 health authorities to manage breakthrough infections and to develop an effective  
91 booster vaccination strategy for more vulnerable individuals.

92  
93 We previously developed a rapid paper-based SARS-CoV-2 neutralization assay  
94 known as cellulose pulled-down virus neutralization test (cpVNT) that detects SARS-  
95 CoV-2 neutralizing antibody (nAb) in plasma or serum within 10 minutes <sup>10</sup>. The  
96 principle of cpVNT is based on the complex formation between the receptor binding  
97 domain (RBD) of the SARS-CoV-2 and the angiotensin converting enzyme II receptor  
98 (ACE2) of the host cell. The RBD is fused with cellulose binding domain (RBD-CBD)  
99 to enable capture by cellulose paper while ACE2 is conjugated with reporting  
100 molecules for signal generation. The presence of nAb in the sample disrupts RBD-  
101 CBD/ACE2 complex formation leading to a reduction in the overall signal detected. To

102 develop a PoC nAb detection test, we improved our cpVNT assay enabling it to be  
103 used directly on whole venous or capillary blood including finger stick blood samples.  
104 This bypasses the requirement for extensive sample processing or a phlebotomist.  
105 Comparison of this modified cpVNT test with established pVNT as well as an ELISA-  
106 based assay showed high degree of concordance. Importantly, the modified cpVNT  
107 test can be easily adapted for the rapid evaluation of nAb responses to SARS-CoV2  
108 variants among vaccinated population, providing critical insights into changes in nAb  
109 responses to vaccine types, variant mutations, and time post vaccination.

110

## 111 **2 RESULTS**

### 112 **2.1 Rapid detection of SARS-CoV-2 neutralization antibody in blood using** 113 **modified cpVNT**

114 To adapt the previous cpVNT for the analysis of whole blood PoC diagnostic samples  
115 it was important to change the enzyme/substrate-based reporter system of HRP/TMB  
116 as well as the overall assay workflow. The two key modifications introduced are (i) the  
117 change to a fluorescent reporter molecule and (ii) sequential incubation steps (Fig. 1A,  
118 S1A). For this, we selected Alexa Fluor® 594 as the reporter in consideration of its  
119 high quantum yield, excellent photostability, and minimal interference with blood. In  
120 addition, to improve the test performance and minimize the non-specific background  
121 from whole blood sample, we altered the cpVNT workflow to a two-step incubation, as  
122 compared to the one-step incubation reported previously. First, 20  $\mu$ L of blood sample  
123 was mixed with 20  $\mu$ L of 10 nM RBD-CBD for 3 minutes before adding 40  $\mu$ L of 5 nM  
124 fluorescence labelled human ACE2 (ACE2-AF594) and incubating for additional 5  
125 minutes at ambient temperature. Equal amount of the final 80  $\mu$ L mixture was then  
126 applied to the cassette's test and control spot respectively followed by one washing  
127 step with 40  $\mu$ L of PBS for each spot (Fig. 1A & B). The additional 3 minutes incubation  
128 step introduced in this study allowed nAb in the blood sample to effectively interact  
129 with RBD-CBD prior to exposure to ACE2 (Fig. S1 B & C).

130

131 Since the presence of nAb is inversely related to the fluorescence intensity, a control  
132 reaction is necessary to verify the reagent functionality, as the loss of signal should  
133 only be due to the presence of nAb. Therefore, we pre-immobilized the control spot  
134 with 5  $\mu$ L of 5  $\mu$ M of RBD-CBD on the cellulose paper to capture ACE2-AF594 free  
135 from RBD-CBD/ACE2-AF594 complex and produce high level of fluorescent signal

136 regardless of the level of nAb present in the blood (Fig. 1A, S1 D). A portable  
137 fluorescent reader, Atto Testbed produced by Attonics Systems Pte. Ltd., Singapore  
138 is customized to allow the detection of fluorescence signal under a PoC setting. The  
139 reader excites the fluorophores using LED light. The emitted fluorescent intensity is  
140 then detected using a silicon avalanche photodiode and reported as a voltage change  
141 in mV unit. This voltage output (mV) can be converted to percentage of blocking  
142 according to Equation 1:

143

$$144 \quad \% \text{ Blocking} = \left( 1 - \frac{\text{Voltage output of test spot} - \text{Baseline}}{\text{Voltage output of Negative control, NC} - \text{Baseline}} \right) \times 100\%$$

145

146 To evaluate this new test format, we made a series of contrived blood samples by  
147 spiking 1, 5, 10, 25, 50 and 100 nM of mouse monoclonal SARS-CoV-2 nAb into a  
148 blood prepared with pre-SARS-CoV-2 pandemic plasma and washed red blood cells.  
149 The assay demonstrated an IC<sub>50</sub> of 3.38 nM nAb using blood as sample matrix (Fig.  
150 1C & D).

151

## 152 **2.2 Evaluation of post vaccination nAb responses using modified cpVNT.**

153 Modified cpVNT relies on the reduction of fluorescent signal in response to neutralizing  
154 antibodies competing with labelled ACE2. Two important fluorescent signals  
155 contribute to the determination of the signal dynamic range and nAb result  
156 interpretation, (i) the maximum fluorescence intensity obtained from negative control  
157 (NC) samples with no nAb (pre-vaccination, Pre-Vac samples); this value was used to  
158 set a reference point for calculation of blocking percentage in the presence of nAb and  
159 (ii) non-specific background fluorescence observed from the test when RBD-CBD was  
160 absent from the reaction; this value was used to draw a baseline between specific and  
161 non-specific signals (see Equation 1). The NC value was defined by the median of  
162 fluorescence intensity measured from 60 Pre-Vac blood samples in triplicates (Fig  
163 S2A), while the baseline value was the median of triplicate reads from 31 blood  
164 samples regardless of vaccination status when RBD-CBD was absent (Fig S2B). With  
165 this approach, the NC value using two independent batches of ACE2-AF594 resulted  
166 in a median fluorescence intensity of 1141 mV (Table S1 and Fig S2A) while the  
167 baseline signal had a median intensity value of 230 mV (Fig S2B). To calculate the

168 percentage of blocking based on the nAb levels of individual, we then applied the NC  
169 as well as baseline value to formulate Equation 1.

170

171 Once NC and the baseline were established, the nAb levels that block RBD and ACE2  
172 interaction were measured in 170 blood samples using modified cpVNT at different  
173 stages of vaccination: pre-vaccination (Pre-Vac), 1-2 weeks post 1<sup>st</sup> dose (P1 1-2W),  
174 3-6 weeks post 1<sup>st</sup> dose (P1 3-6W) and 3-16 weeks post 2<sup>nd</sup> dose (P2). The Pre-Vac  
175 (n=36) group's percent blocking was measured with a median of 1.96%, this number  
176 increased to 14.3% in P1 1-2W group (n = 10) and P1 3-4W group at 36.5% (n = 50).  
177 Lastly, we observed 89.1% for P2 samples (n=74) (Fig. 2A). A similar trend was  
178 observed when grouping the samples into individuals vaccinated with either  
179 BNT162b2 (Fig 2B) or mRNA-1273 (Fig 2C). The negative value of percent blocking  
180 observed in the Pre-Vac and P1 1-2W was likely due to viscosity variation among  
181 blood samples that could interfere with the binding kinetics of RBD-CBD with cellulose  
182 paper in the assay. Overall, the data showed a significant difference between Pre-Vac  
183 and P1 3-6W samples across the two different types of vaccines, i.e. BNT162b2  
184 (p<0.05) and mRNA-1273 (p<0.001) (Fig 2B & C). There was also a significant  
185 difference (p<0.05) in median percent blocking for P1 3-6W group when compared  
186 between BNT162b2 recipients (23.4%, n=30) and mRNA-1273 recipients (51.2%,  
187 n=20) (Fig 2D). However, in P2 samples, both vaccines show comparable median  
188 percent blocking at 84.5% for BNT162b2 and 90.9% for mRNA-1273 recipients (Fig  
189 2B & C). Mapping of the nAb response in 22 individuals who received either BNT162b2  
190 or mRNA-1273 showed differential responses at P1 phase (Fig 2E). Both vaccines  
191 induced a heterogeneous though elevated response in all individuals tested as early  
192 as week 2 post first dose of vaccine.

193

### 194 **2.3 Modified cpVNT can detect wide range of nAb activities comparable to sVNT** 195 **and pVNT.**

196 We used the WHO International Standard for anti-SARS-CoV-2 immunoglobulin  
197 (20/136) and Reference Panel (20/268) to assess the detection range of modified  
198 cpVNT and to better interpret the clinical data we have measured <sup>11</sup>. The International  
199 Standard comprising of plasma sample with assigned 1000 IU/mL nAb activity resulted  
200 in 96.7% blocking in our modified cpVNT (Fig 3A). This percent blocking corresponded  
201 to the value observed from subjects in the P2 vaccination group (Fig. 2A). The Mid-



202 titre and Low-titre plasma from WHO Reference Panel with 210 IU/mL and 44 IU/mL  
203 nAb activity respectively were measured with 66.7% blocking (Mid) and 34.9%  
204 blocking (Low) in the modified cpVNT (Fig 3A). This showed that the test can produce  
205 a dose dependent response that captures the clinical range of nAb activity in plasma  
206 in under 10 minutes assay time. Since plasma represents approximately 55% of whole  
207 blood, the percent blocking test results in plasma samples was expected to be higher  
208 than that of whole-blood due to the lack of erythrocytes. To correlate the percent  
209 blocking in the WHO standard and reference panel plasma to corresponding whole  
210 blood, we analyzed 30 matching samples of blood and plasma in the modified cpVNT.  
211 We found that the percent blocking in blood samples is approximately 0.87 times of  
212 that in plasma samples assuming the relationship between the two sample types are  
213 linear (Fig 3B). We observed that the overall median percent blocking in Pre-Vac  
214 samples was found below 30% blocking in modified cpVNT using blood as matrix (Fig  
215 2A). It corresponds to 44 IU/mL neutralizing antibody activity which is close to the  
216 estimated protective neutralization against SARS-CoV-2 of approximately of 54 IU/mL  
217 by Khoury et al.'s predictive model <sup>12</sup> (Fig 3B). Hence, 30% blocking which correlates  
218 to 44 IU/mL was set as the cut-off value for the modified cpVNT to compare its  
219 performance with other neutralization tests (Fig 3B). Our test showed 81.5%  
220 sensitivity (CI 61.9-93.7%) and 100% specificity (CI 81.5-100%) when compared with  
221 the commercially available sVNT Genscript cPass™ (Fig 3C). Meanwhile, as  
222 compared to the lab based pVNT test, the modified cpVNT showed 100 % sensitivity  
223 (CI 47.8 - 99.9%) and 66.7% specificity (CI: 38.4 - 88.2%) (Fig 3D). For reference, the  
224 WHO plasma of nAb activity at 1000 IU/mL, 210 IU/mL and 44 IU/mL when performed  
225 with sVNT cPass yielded 94 %, 78% and 19% inhibition respectively (Table S3). The  
226 lower specificity and sensitivity relative to ELISA and pVNT can be attributed to the  
227 difference in sample type (whole blood vs plasma/serum) and different assay  
228 procedures.

229 To ensure that the modified cpVNT is suitable for PoC setting with finger stick blood,  
230 we assessed the correlation of nAb detected in venous vs finger-stick blood sample  
231 matrix. A total of 46 matched pairs from Pre-Vac, P1 and P2 samples show a high  
232 linear correlation between the two blood sample types, with a Pearson r value of  
233 0.9758 (p value < 0.001) and an R<sup>2</sup> of 0.9523 (Fig S2C). This demonstrates the  
234 suitability of our modified cpVNT for PoC deployment, as only 20 µL of finger-stick

235 blood samples is necessary to measure the nAb response in 10 minutes. Moreover,  
236 the outcomes are comparable to established lab-based neutralization tests.

237

#### 238 **2.4 Assessment of post-vaccinated nAb percent blocking against SARS-CoV-2** 239 **variant RBDs**

240 Given the emergence of several SARS-CoV-2 variants and the accompanying  
241 uncertainty of the effectiveness of vaccine-induced nAbs against them, there has been  
242 burgeoning interest in evaluating nAb responses to variant RBDs. In light of this, we  
243 first recombinantly produced 4 variants of concern (VOCs): alpha B.1.1.7, beta  
244 B.1.351, gamma P.1, delta B.1.167.2 and 5 variants of interest (VOIs): kappa  
245 B.1.167.1, epsilon B.1.427/B.1.429, delta plus AY.1, eta B.1.525, lambda C.37 fused  
246 with CBD and evaluate their binding activity with ACE2 using Biolayer-Interferometry  
247 (BLI) (Fig. S3 & S4A). These variants contain mutations in the RBD region, which may  
248 reduce the binding affinities of antibodies generated against the wildtype protein  
249 and/or increase ACE2 receptor binding<sup>13</sup>. We found that the binding affinity of alpha,  
250 beta, gamma, and delta are higher than that of wildtype (WT), especially gamma that  
251 showed a 3 -fold increase (4.3 nM) in binding affinity comparing to wild-type (12.7 nM)  
252 consistent with previous report<sup>13,14</sup> (Table 1). Furthermore, our result supports  
253 published data that the N501Y mutation in the alpha, and gamma variants of RBD  
254 contributes to the slow off-rate of the complex<sup>15</sup> (Table 1). Meanwhile T478K appears  
255 to promote fast complex formation based on comparison among delta, kappa, epsilon,  
256 and a delta plus variant that shared the L452R mutation (Table 1). We engineered a  
257 hypothetical RBD variant containing N501Y, T478K mutation and annotated it as 'AD'  
258 (alpha-delta) variant that is speculated to have fast on-rate and slow off-rate with ACE2.  
259 This hypothetical variant confirmed our hypothesis where it binds ACE2 with the  
260 highest binding affinity (KD of 3 nM) among the 10 variants (Table 1). Next, we assess  
261 the activity of these RBD-CBD variants on the modified cpVNT with Pre-Vac blood.  
262 Although variants with high affinity to ACE2 showed increased fluorescence intensity  
263 than WT RBD-CBD in the modified cpVNT assay at the same reagent concentration,  
264 ie. alpha (1.8-fold), beta (1.6-fold), gamma (2.1-fold), delta (1.3-fold), the correlation is  
265 not direct. As we observed variant RBD-CBDs epsilon and lambda still generate  
266 comparable signal as WT despite the lower ACE2 binding affinity, while AD variant  
267 showed merely 1.6-fold increase in signal despite binding ACE2 strongly (Fig. S4A).



268 Besides the binding kinetics, the capture rate of RBD-CBD on the cellulose paper and  
269 possible avidity of the different RBD-variants on ACE2 could contribute to the effect.

270

271 We then tested the 4 VOCs: RBD-CBD alpha, beta, gamma, and delta with 33 blood  
272 samples from participants within 3 months of completing vaccination. There were  
273 considerable variations in the nAb responses to the different variants. The nAb percent  
274 blocking against beta and gamma variants being reduced significantly to 72.4 % and  
275 70.1%, while the percent blocking reduced only minimally to 87.2% and 91.9% for  
276 alpha and delta respectively as compared to WT (95.6%) (Fig 4A). These were in line  
277 with previous reports using pVNT and VNT, whereby neutralization of beta and gamma  
278 variants had considerable reduction for both mRNA vaccines<sup>16-18</sup>. About 91.8% nAb  
279 blocking was observed against the engineered AD variant even though the RBD-CBD  
280 variant binds strongly to ACE2, suggesting that vaccine induced nAb can outcompete  
281 stronger interaction (Fig S4B). While this data indicated a heterogenous response it  
282 was important to evaluate whether our test was able to stratify response in relation to  
283 the different vaccines used. The median percent blocking for BNT162b2 recipients  
284 against alpha was 78% ( $p < 0.01$ ) and delta was 89.2% ( $p = n.s.$ ) as compared to WT  
285 (94.8%). (Fig 4B). The most substantial reductions of nAb response were observed  
286 with beta and gamma variants reaching 55.7% and 49.6% blocking respectively  
287 among BNT162b2 recipients (Fig 4B). In the cohort of mRNA-1273 recipients, we  
288 observed reduction to 87.5% with beta variant ( $p < 0.0001$ ) and 80.5% with gamma  
289 variant ( $p < 0.0001$ ).

290

291 Next, we also examined and compared the percent blocking of nAb in whole-blood  
292 samples from participants within three months or greater than three months after  
293 completion of vaccination against WT and 4 VOCs RBD-CBD. Only samples from  
294 BNT162b2 recipients were available to us for the greater than three months cohort as  
295 it was the first vaccine rolled-out in the Singapore national vaccination program. There  
296 was a modest drop of nAb percent blocking from 96% to 68% (28%,  $p < 0.0001$ )  
297 observed in WT RBD-CBD and 77.6% to 40.2% (37.4%,  $p < 0.001$ ) in alpha RBD-CBD  
298 between the two groups of samples (Fig 4D). Meanwhile a more substantial reduction  
299 was seen in beta (47.8%,  $p < 0.0001$ ), gamma (49.5%,  $p < 0.001$ ) and delta variant  
300 (53.5%,  $p < 0.0001$ ) respectively (Fig 4D). It is interesting to observe the stark decline  
301 of nAb blocking for delta variant in the post 3 months cohort especially when no

302 significant difference of nAb response was detected from WT for samples vaccinated  
303 within 3 months (Fig 4A). The modified cpVNT results agree with recent findings where  
304 BNT162b2 vaccine induced protection wanes within 4-5 months especially against the  
305 delta variant despite earlier findings suggest effective neutralization<sup>19,20</sup>. This  
306 demonstrates that this test can be effectively adapted in the event of future VOC  
307 emergence to quickly assess vaccinees' responses and even to identify vulnerable  
308 individuals for booster shots to prevent breakthrough infections.

309

### 310 **3 DISCUSSION**

311 The rapid modified cpVNT can improve our understanding of the relationship between  
312 nAb response and RDB/ACE2 interaction, especially in response to emerging and  
313 predictive mutants. Given the complex innate and cell mediated immune response  
314 against infection and immune-protection development, factors like synergistic  
315 mutations and epitope remodelling to prevent nAb recognition are key to a variant's  
316 immune escape characteristics<sup>21</sup>. We tested the influence of RBD/ACE2 interaction  
317 on nAb blocking with the hypothetical AD variant that carries N501Y T478K mutation.  
318 It was found unable to evade vaccine induced nAb inhibition where it shows 91.8%  
319 nAb blocking in the modified cpVNT similar to WT RBD-CBD despite its high affinity  
320 to ACE2 (Fig S4B). Since a single T478K mutation did not present compromising effect  
321 on the binding of potent neutralizing mAbs previously<sup>22</sup>, we observed that the  
322 additional N501Y mutation in AD variant does not affect nAb binding within the  
323 modified cpVNT's reaction time (Fig S4B). In contrast, the beta variant despite  
324 showing modest increase in affinity towards ACE2 ( $K_D$  9.6 nM) than WT ( $K_D$  12.7 nM),  
325 exhibited significantly lower nAb percent blocking than WT (Fig. 4A). As the K417 and  
326 E484 sites are known to escape both class 1 and class 2 anti-RBD antibodies<sup>23</sup>, the  
327 combined effect of RBD/ACE2 binding and poor nAb recognition generate more  
328 pronounced immune escape response. These examples indicate that the modified  
329 cpVNT can be used to systematically assess the RBD mutations and improve our  
330 understanding of its underlying molecular mechanism versus nAb response.

331

332 With the emergence of highly transmissible SARS-CoV-2 variants, the durability and  
333 persistence of vaccine effectiveness is of major concern. Although nAb response  
334 strongly correlates with immune protection<sup>12</sup>, cellular immunity is essential in providing  
335 sustained immune protection upon exposure, particularly against severe illness.

336 Therefore, both humoral and cellular immune response are required for a complete  
337 assessment of SARS-CoV-2 immunity. While standardized methods for rapid  
338 assessment of cellular immunity responses are underway <sup>24</sup>, nAb level measurement  
339 remains a reliable indicator for immune-protection at PoC level and deems to be critical  
340 at this point. It has been estimated that 90% of convalescent plasma/sera's  
341 neutralizing activity targets the immunodominant RBD <sup>25-27</sup>, hence the current  
342 modified cpVNT format that measures the nAb response to RBD-associated mutations  
343 represents a good proxy for assessing individual's immune protection. The  
344 standardized percent blocking provided by the customized reader, permits consistent  
345 results interpretation as opposed to colorimetric scoring. Besides, as demonstrated  
346 here, the test only requires a simple change in one reagent while retaining the test  
347 format, instrumentation, and capability to evaluate nAb responses to a new variant.  
348 This feature is quintessential for keeping up with the rapidly evolving virus, for example  
349 the new mu variant in Colombia that was reported to escape vaccine induced immunity  
350 <sup>28</sup>.

351  
352 Our data also shows the strength of the modified cpVNT as a PoC test to provide  
353 insights on the deteriorating vaccine efficacy observed globally against the delta  
354 variant and the climbing breakthrough infections among vaccinated population. The  
355 significant decline of nAb response against the delta variant observed among post 3  
356 months's BNT162b2 vaccinees in our study provides a possible reason for the  
357 increased breakthrough infections observed globally. The report that BNT162b2  
358 recipients who completed their vaccination between Jan-April in Israel had an  
359 increased risk of breakthrough infections with delta variant is in line with our  
360 interpretation <sup>29</sup>. Thus, our test's ability to detect variant specific nAb waning effects  
361 among a vaccinated population provides an extremely valuable tool to pre-emptively  
362 test nAb responses against emerging variants and through this inform booster  
363 planning and public health management.

364

## 365 **4 MATERIALS AND METHODS**

### 366 **4.1 Study participants**

367 Heathy adults age between 21-65 years old scheduled for Singapore national  
368 vaccination program were enrolled to the study in compliance with all relevant ethical  
369 regulations and was approved by Institutional Review Board of Nanyang

370 Technological University (IRB-2021-04-020). All participants provided informed  
371 consent before participation under voluntary basis and reported with no prior SARS-  
372 CoV-2 infection at point of recruitment. The venous blood collection was performed by  
373 certified phlebotomists while finger-prick blood was collected using Haim® Winnoz  
374 blood collection device or manual collection. Pre-SARS-CoV-2 plasma samples were  
375 collected under IRB 003/2010, IRB 11/08/03, IRB 13/09/01 and IRB-2016-01-045  
376 stored in -80°C. Whole-blood samples from healthy volunteers vaccinated more than  
377 3 months was provided by National Centre of Infectious Diseases (NCID) under DSRB  
378 2012/00917. There were no breakthrough infections reported from these samples.  
379

#### 380 **4.2 Blood sample processing and storage**

381 Blood samples were kept at 4°C for delivery, venous blood storage in heparin tubes  
382 (BD Vacutainer® #367874) while finger stick blood were stored in either heparin (Xinle  
383 Medical MP0540) or EDTA (Xinle Medical MP0581) microtainer tubes. A portion of the  
384 sample volume was separated into plasma content by centrifugation at 4000 g for 5  
385 minutes in 4°C. Plasma were stored in -20°C. Both WHO International Standard  
386 (20/136) and Reference Panel for anti-SARS-CoV-2 immunoglobulin (20/268) plasma  
387 were purchased from National Institute for Biological Standards and Control (NIBSC,  
388 United Kingdom) and were stored in -20 °C upon receipt.  
389

#### 390 **4.3 Protein production and purification**

391 The expression and purification of soluble extracellular fragment of human ACE2  
392 (residues 19–615; GenBank: AB046569.1) and wildtype (WT) SARS-CoV2-Spike  
393 (EMBL: QHD43416.1 with silent mutations c.A1452>G and c.T1470>C) RBD fused to  
394 CBD followed the same protocol as described in Kongsuphol et al. <sup>10</sup>. Similarly, alpha  
395 c.A1501>T (p.N501Y), beta c.A1501>T, c.G1251>C, c.G1450>A (p.N501Y K417N  
396 E484K), gamma c.A1501>T, c.A1250>C, c.G1450>A (p.N501Y K417T E484K), delta  
397 c.T1355>G, c.C1433>A (p.L452R T478K), kappa c.T1355>G, c.G1450>C (p.L452R  
398 E484Q), epsilon c.T1355>G (p.L452R), delta plus c.T1355>G, c.C1433>A,  
399 c.G1450>A (p.L452R T478K K417N ), eta c.G1450>A (p.E484K) , lambda c.T1355>A  
400 c. T1469>C (p.L452Q, F490S) and AD c.A1501>T, c.C1433>A (p.N501Y T478K)  
401 RBD-CBD variants were expressed in Expi293F cells (Thermo Fisher Scientific,  
402 A1435101) according to the supplier's protocol. The purification protocol followed that

403 of WT RBD-CBD. In brief, the proteins were subjected to affinity chromatography with  
404 Ni-NTA cartridges (Qiagen, 1046323) and size exclusion chromatography with HiLoad  
405 16/60 Sephadex 200 (Cytiva) in 20 mM HEPES pH 7.5, 300 mM NaCl, 10% glycerol.  
406 The His-MBP tag of RBD-CBD variants were removed by incubation with TEV  
407 protease overnight in 1:40 mass ratio at 4°C. The untagged proteins were further  
408 purified by reverse affinity chromatography with HisPur-Ni-NTA resin in 20 mM HEPES  
409 pH 7.5, 300 mM NaCl, 10 mM Imidazole. Lastly, the purified RBD-CBD variants were  
410 concentrated and stored in 20 HEPES pH 7.5, 300 mM NaCl, 10% glycerol and 0.5  
411 mM TCEP at -80°C.

412

#### 413 **4.4 Fluorescence conjugation of monoFc-ACE2**

414 Alexa Fluor® 594 conjugation of monoFc-ACE2 was carried out by using Alexa Fluor®  
415 594 Conjugation Kit (Fast) - Lightning-Link® (abcam, ab269822). For each labeling  
416 reaction, 100 µL of 1 mg/mL of monoFc-ACE2 in Phosphate Buffer Saline (PBS) pH  
417 7.6 was mixed with 10 µL of Modifier reagent. The 110 µL of mixture was transferred  
418 to Alexa Fluor® 594 Conjugation Mix followed by 30 minutes incubation at room  
419 temperature in the dark. Then, the reaction was stopped by adding 10 µL of Quencher  
420 reagent and for 15 minutes incubation in the dark. Finally, the labelled protein was  
421 stored in aliquots of 5 µL at – 80°C freezer before use.

422

#### 423 **4.5 Cellulose pulldown virus neutralization test (cpVNT)**

424 Every testing cassette was assembled by using 1 layer of Whatman No. 1  
425 chromatography paper (GE healthcare, #3001-861) as cellulose test strip and 2 layers  
426 of Whatman gel blotting paper, Grade GB005 (GE healthcare, #10426981) as  
427 absorbent pads into a cassette housing (Racer Technology Pte. Ltd.). Then, both the  
428 test and control spots were blocked with 5 µL of 5% Bovine Serum Albumin (BSA) in  
429 PBS pH 7.6. The control spot is further treated with 5 µL of 5 µM RBD-CBD before air-  
430 dry. For each test, 20 µL of venous or finger pricked whole blood sample was first  
431 incubated with 20 µL of 10 nM RBD-CBD in PBS pH 7.6, 1% BSA for 3 minutes. After  
432 that, 40 µL of 5 nM Alexa Fluor594 labelled monoFc-ACE2 (ACE2-AF594) in PBS pH  
433 7.6, 1% BSA was added to the mixture and incubated for another 5 minutes. The final  
434 80 µL reaction was applied equally onto the test and control spot with 40 µL for each.  
435 Once sample was fully absorbed, both test and control spots were washed once with

436 40  $\mu$ L of PBS pH 7.6. The cassette was then placed in an Atto Testbed for fluorescence  
437 measurement. All steps described above were performed at room temperature.

438

#### 439 **4.6 Fluorescence Measurement and Percent Blocking calculation**

440 The Atto Testbed (Attonics Systems Pte Ltd) comprised of an LED lamp (Thorlabs Inc.,  
441 M590L4), Silicon Avalanche Photodiode detector (SiAPD) (Thorlabs Inc., APD440A)  
442 and mCherry filter set (Thorlabs Inc., MDF-MCHA) including an Excitation filter  
443 (578/21), an Emission filter (641/75) combined with a dichroic beam-splitter. The  
444 testbed was designed specifically to fit the testing cassette dimension for fluorescent  
445 signal detection. Fluorescence intensity was recorded as SiAPD output in mV. The  
446 percent blocking was calculated using the Equation 1 (see Results section). All  
447 samples were tested in triplicates with their mean represented as single data point and  
448 the median percent blocking of each group with a given sample size was reported.

449

#### 450 **4.7 Surrogate virus neutralization assay cPass (Genscript)**

451 The assay was performed as per manufacturer's protocol by first diluting the selected  
452 plasma samples 1:10 in the sample dilution buffer provided by the kit, and incubated  
453 with HRP-conjugated RBD for 30 minutes at 37°C. Then, the sample-RBD mixtures  
454 were transferred to an ACE2 coated ELISA plate for 15 minutes incubation at 37°C  
455 before washing with the kit's washing solution. The sample read-out was performed  
456 by adding 100  $\mu$ L 3,3',5,5'-tetramethylbenzidine (TMB) solution per reaction well for  
457 15 minutes, followed by 50  $\mu$ L of stop solution. Absorbance was measured at 450 nm  
458 using Infinite 200 PRO multimode TECAN plate reader and the percent of inhibition  
459 were calculated according to manufacturer's recommendation.

460

#### 461 **4.8 Bio-layer Interferometry (BLI)**

462 The streptavidin biosensor tips (Sartoris) were pre-incubated with 20 nM of the  
463 monoFc-ACE2, chemically biotinylated with EZ-link Sulfo-NHS-LC-Biotinylation kit  
464 (Thermo Fisher, #21435). The binding of WT and all RBD-CBD variants were  
465 measured as optical thickness response for 600s of association phase followed by  
466 900s of dissociation phase. The concentration of RBD-CBDs were prepared in serial  
467 dilutions ranging from 3.125 - 100 nM (except for gamma RBD-CBD; 2.5 - 80 nM).  
468 Analysis of binding response was performed by Octet Data Analysis software using



469 global 1:1 fitting for  $K_D$  calculation. All experiments were performed using 8-channel  
470 Octet RED96e system (Forté Bio) in PBS, 0.2% BSA and 0.05% Tween 20 at 25°C.

#### 471 **4.9 SARS-CoV-2 pseudovirus neutralization assay**

472 We applied the same protocol for production of SARS-CoV-2 pseudotyped lentiviral  
473 particles and pseudovirus neutralization assay as previously reported<sup>10</sup>. Briefly, to  
474 produce SARS-CoV-2 pseudovirus, HEK293T cells at  $36 \times 10^6$  cell density were  
475 transfected with 27  $\mu\text{g}$  pMDLg/pRRE (Addgene, #12251), 13.5  $\mu\text{g}$  pRSV-Rev  
476 (Addgene, #12253), 27  $\mu\text{g}$  pTT5LnX-WHCoV-St19 (SARS-CoV2 Spike) and 54  $\mu\text{g}$   
477 pHIV-Luc-ZsGreen (Addgene, #39196) using Lipofectamine 3000 (Invitrogen,  
478 #L3000-150). Then the cells were grown for 3 days in 37°C, 5% CO<sub>2</sub> incubator.  
479 Harvested and filtered viral supernatant were concentrated and quantified by using  
480 Lenti-X p24 rapid titer kit (Takara Bio, #632200). Twenty pre and post vaccinated  
481 individual plasma were diluted to 1:80 titre with PBS and mixed with equal volume of  
482 pseudovirus to 50  $\mu\text{L}$  followed by 1h incubation at 37°C. The neutralization assay was  
483 performed by transferring the plasma-pseudovirus mixture to monolayered CHO-  
484 ACE2 cells ( $5 \times 10^4$  cells) in 100 $\mu\text{L}$  of complete medium containing DMEM/high glucose  
485 with sodium pyruvate (Gibco, #10569010), 10% FBS (Hyclone, # SV301160.03), 10%  
486 MEM Non-essential amino acids (Gibco, #1110050), 10% geneticin (Gibco,  
487 #10131035) and 10% penicillin/streptomycin (Gibco, #15400054). After 1hr incubation,  
488 150  $\mu\text{L}$  of complete medium were added for subsequent 48hr infection. Each plasma  
489 samples were tested in triplicates. The read-out was performed on Tecan Spark 100M  
490 after luciferase assay with ONE-glo™ EX reagent (Promega, #E8130) where the  
491 percent of neutralization was determined by:

492

$$493 \quad \text{Neutralization \%} = \frac{\text{Readout (unknown)} - \text{Readout (infected control)}}{\text{Readout (uninfected control)} - \text{Readout (infected control)}} * 100\%$$

#### 494 **4.10 Statistical Analysis**

495 Neutralization antibody (nAb) response was represented by the median % blocking in  
496 our results. Since we do not assume a normal distribution, a non-parametric Kruskal-  
497 Wallis test with Dunn multiple comparison was performed for comparing Pre-Vac, post  
498 1<sup>st</sup> dose (1-3 weeks), post 1<sup>st</sup> dose (3-6 weeks) and post 2<sup>nd</sup> dose vaccination groups.  
499 Meanwhile two-sided Mann-Whitney test was performed for the two-group comparison

500 in analyzing between (i) BNT162b2 and mRNA-1273 post 1<sup>st</sup> dose (3-6weeks)  
501 vaccinated samples and (ii) nAb response within 3 months and post 3months cohorts.  
502 The Friedman test with multiple comparison was performed for the same sample set  
503 that repeated against RBD-CBD WT and the variants.

504

## 505 **ACKNOWLEDGEMENTS**

506 We thank all the IRB-2021-04-020 and DSRB 2012/00917 volunteers for their  
507 participation throughout the study. We are grateful for the phlebotomists from National  
508 University Hospital, NUS Occupational Health Clinic and Fullerton Healthcare @ NTU  
509 for their assistance. The pHLmMBP-10 vector used in the cloning of WT and variant  
510 RBD-CBDs was a gift of Luca Jovine, Department of Biosciences and Nutrition,  
511 Karolinska Institutet, Sweden. Meanwhile, the TEV protease was a kind gift of NTU  
512 Protein Production Platform (proteins.sbs.ntu.edu.sg). We thank Assoc Prof. Tan Yee  
513 Joo, Department of Microbiology and Immunology, Yong Loo Lin, School of Medicine,  
514 National University of Singapore (NUS) for the CHO-ACE2 stable cell line and SARS-  
515 CoV-2 S protein plasmid for the pseudotyped lentiviral particle production. We also  
516 greatly appreciate Prof. Herbert Moser and Dr. Felix Neugart from Attonics Inc. for  
517 their scientific input. This study is supported by National Health Innovation Singapore  
518 (NHIC) grant # NHIC-COVID19-2005004, National Research Foundation via CREATE  
519 Share grant #R571-002-021-592 and the Antimicrobial Resistance Interdisciplinary  
520 Research Group (AMR-IRG) of Singapore -MIT Alliance in Research and Technology  
521 (SMART). All samples acquired from National Centre of Infectious Diseases (NCID)  
522 were supported by Singapore Ministry of Health's National Medical Research Council  
523 COVID-19 Research Fund: COVID19RF-0008.

524

## 525 **AUTHOR CONTRIBUTIONS**

526 S.M.L., H.L.C., H.J., P.K., conceived and designed the experimental study. H.J. and  
527 P.K. supervised the method development. H.L.C. and S.M.L. performed modified  
528 cpVNT experiments and analyzed the data. S.M.L. wrote the manuscript. B. S.  
529 performed the pVNT assays. M.W.C. produced the recombinant proteins. S.Y.N  
530 prepared the cassettes and cellulose papers. X.G. prepared IRB application and  
531 obtained the IRB approval. S.P.T. and S.F.H. designed and developed the portable  
532 reader device. J.S., S.S. and B.E.Y. provided the post 3 months vaccinated blood  
533 samples. D.M.Y.T edited the manuscript. B.E.Y. M.E.M, H.D.S, P.A.M, P.R.P

534 contributed to the discussion, interpretation of the results and revision of the final  
535 manuscript.

536

### 537 **CONFLICT OF INTEREST**

538 PK, MM, HDS, JH and PRP are the cofounders of Thrixen Pte Ltd, a start-up company  
539 working in further developing some of the technology presented here.

540

### 541 **REFERENCES**

- 542 1. Bergwerk M, Gonen T, Lustig Y, et al. Covid-19 Breakthrough Infections in  
543 Vaccinated Health Care Workers. *N Engl J Med.* 2021;385:1474-1484.  
544 doi:10.1056/NEJMOA2109072
- 545 2. Callaway E. COVID vaccine boosters: the most important questions. *Nature.*  
546 2021;596(7871):178-180. doi:10.1038/d41586-021-02158-6
- 547 3. Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. Three Doses  
548 of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients. *N Engl J*  
549 *Med.* 2021;385(7):661-662. doi:10.1056/nejmc2108861
- 550 4. Oguntuyo KY, Stevens CS, Hung CT, et al. Quantifying absolute neutralization  
551 titers against sars-cov-2 by a standardized virus neutralization assay allows for  
552 cross-cohort comparisons of covid-19 sera. *MBio.* 2021;12(1):1-23.  
553 doi:10.1128/mBio.02492-20
- 554 5. Gundlapalli A V., Salerno RM, Brooks JT, et al. SARS-CoV-2 serologic assay  
555 needs for the next phase of the US COVID-19 pandemic response. *Open Forum*  
556 *Infect Dis.* 2021;8(1). doi:10.1093/ofid/ofaa555
- 557 6. Tan CW, Chia WN, Qin X, et al. A SARS-CoV-2 surrogate virus neutralization  
558 test based on antibody-mediated blockage of ACE2–spike protein–protein  
559 interaction. *Nat Biotechnol.* 2020;38(9):1073-1078. doi:10.1038/s41587-020-  
560 0631-z
- 561 7. Sancilio AE, D’aquila RT, McNally EM, et al. A surrogate virus neutralization test  
562 to quantify antibody-mediated inhibition of SARS-CoV-2 in finger stick dried  
563 blood spot samples. *Sci Rep.* 123;11:15321. doi:10.1038/s41598-021-94653-z
- 564 8. Whitman JD, Hiatt J, Mowery CT, et al. Evaluation of SARS-CoV-2 serology  
565 assays reveals a range of test performance. *Nat Biotechnol.*  
566 doi:10.1038/s41587-020-0659-0
- 567 9. Wang JJ, Zhang N, Richardson SA, Wu J V. Rapid lateral flow tests for the

- 568 detection of SARS-CoV-2 neutralizing antibodies. *Expert Rev Mol Diagnostic.*  
569 2021;21(4):363-370. doi:10.1080/14737159.2021.1913123
- 570 10. Kongsuphol P, Jia H, Cheng HL, et al. A rapid simple point-of-care assay for the  
571 detection of SARS-CoV-2 neutralizing antibodies. *Commun Med.*  
572 doi:10.1038/s43856-021-00045-9
- 573 11. Mattiuzzo G, Bentley EM, Hassall M, et al. Establishment of the WHO  
574 International Standard and Reference Panel for anti-SARS-CoV-2 antibody.  
575 *WHO Expert Comm Biol Stand.* Published online 2020. WHO/BS/2020.2403
- 576 12. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly  
577 predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat*  
578 *Med.* 2021;27:1205-1211. doi:10.1038/s41591-021-01377-8
- 579 13. Gobeil SMC, Janowska K, McDowell S, et al. Effect of natural mutations of  
580 SARS-CoV-2 on spike structure, conformation, and antigenicity. *Science (80- )*.  
581 2021;373(641). doi:10.1126/science.abi6226
- 582 14. Laffeber C, de Koning K, Kanaar R, Lebbink JHG. Experimental Evidence for  
583 Enhanced Receptor Binding by Rapidly Spreading SARS-CoV-2 Variants. *J Mol*  
584 *Biol.* 2021;433(15):167058. doi:10.1016/j.jmb.2021.167058
- 585 15. Zhu X, Mannar D, Srivastava SS, et al. Cryo-electron microscopy structures of  
586 the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent  
587 neutralizing antibodies. *PLoS Biol.* 2021;19(4):1-17.  
588 doi:10.1371/journal.pbio.3001237
- 589 16. Wilfredo Garcia-Beltran AF, Lam EC, St Denis K, John Iafrate A, Naranbhai V,  
590 Balazs Correspondence AB. Multiple SARS-CoV-2 variants escape  
591 neutralization by vaccine-induced humoral immunity. *Cell.* 2021;184:2372-2383.  
592 doi:10.1016/j.cell.2021.03.013
- 593 17. Pegu A, O'Connell S, Schmidt SD, et al. Durability of mRNA-1273 vaccine-  
594 induced antibodies against SARS-CoV-2 variants. *Science.*  
595 2021;373(6561):1372-1377. doi:10.1126/science.abj4176
- 596 18. Bates TA, Leier HC, Lyski ZL, et al. Neutralization of SARS-CoV-2 variants by  
597 convalescent and BNT162b2 vaccinated serum. *Nat Commun.* 2021;12(5135).  
598 doi:10.1038/s41467-021-25479-6
- 599 19. Liu J, Liu Y, Xia H, et al. BNT162b2-elicited neutralization of B.1.617 and other  
600 SARS-CoV-2 variants. *Nature.* 2021;596(7871):273-275. doi:10.1038/s41586-  
601 021-03693-y

- 602 20. Pouwels KB, Pritchard E, Matthews P, et al. Effect of Delta on viral burden and  
603 vaccine effectiveness against new SARS-CoV-2 infections in the UK. *Nat Med*.  
604 Published online 2021. doi:10.1038/s41591-021-01548-7
- 605 21. Harvey WT, Carabelli AM, Jackson B, et al. SARS-CoV-2 variants, spike  
606 mutations and immune escape. *Nat Rev Microbiol*. 2021;19:409-424.  
607 doi:10.1038/s41579-021-00573-0
- 608 22. Liu C, Ginn HM, Dejnirattisai W, et al. Reduced neutralization of SARS-CoV-2  
609 B.1.617 by vaccine and convalescent serum. *Cell*. 2021;184(16):4220-4236.e13.  
610 doi:10.1016/j.cell.2021.06.020
- 611 23. Greaney AJ, Starr TN, Barnes CO, et al. Mapping mutations to the SARS-CoV-  
612 2 RBD that escape binding by different classes of antibodies. *Nat Commun*.  
613 2021;12(1). doi:10.1038/s41467-021-24435-8
- 614 24. Tan AT, Lim JME, Bert N Le, et al. Rapid determination of the wide dynamic  
615 range of SARS-CoV-2 Spike T cell responses in whole blood of vaccinated and  
616 naturally infected. *J Clin Invest*. 2021;131(17). doi:10.1172/JCI152379.
- 617 25. Piccoli L, Park YJ, Tortorici MA, et al. Mapping Neutralizing and  
618 Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by  
619 Structure-Guided High-Resolution Serology. *Cell*. 2020;183(4):1024-1042.e21.  
620 doi:10.1016/j.cell.2020.09.037
- 621 26. Robbiani DF, Gaebler C, Muecksch F, et al. Convergent antibody responses to  
622 SARS-CoV-2 in convalescent individuals. *Nature*. 2020;584(7821):437-442.  
623 doi:10.1038/s41586-020-2456-9
- 624 27. Shi R, Shan C, Duan X, et al. A human neutralizing antibody targets the  
625 receptor-binding site of SARS-CoV-2. *Nature*. 2020;584(7819):120-124.  
626 doi:10.1038/s41586-020-2381-y
- 627 28. Uriu, Keiya; Kimura, Azumi; Shirakawa, Kotaro; Takaori-Kondo, Akifumi;  
628 Nakada, Taka-aki; Kaneda, Atsushi; Nakagawa, So; Sato K. Neutralization of  
629 the SARS-CoV-2 Mu variant by convalescent and Vaccine Serum. *N Engl J Med*.  
630 Published online 2021. doi:10.1056/NEJMc2114706
- 631 29. Mizrahi B, Lotan R, Kalkstein N, et al. Correlation of SARS-CoV-2 Breakthrough  
632 Infections to Time-from-vaccine. *Nat Commun*. 2021;12:6379.  
633 doi:10.1038/s41467-021-26672-3  
634

635 **TABLE 1: Binding kinetics of wildtype and RBD-CBD variant with biotinylated**  
636 **ACE2**

RBD	Lineage name	Mutation on RBD	Binding affinity, $K_D$ (nM)	$k_a$ (1/Ms)	$k_{dis}$ (1/s)
WT			12.7	99200	0.00127
alpha	B.1.1.7	N501Y	8.17	122000	0.000997
beta	B.1.351	N501Y, K417N, E484K	9.59	132000	0.00126
gamma	P.1	N501Y, K417T, E484K	4.3	220000	0.000954
delta	B.1.167.2	L452R, T478K	9.19	231000	0.0021
kappa	B.1.167.1	L452R, E484Q	22.2	70400	0.00156
epsilon	B.1.427/B.1.429	L452R	20.7	96900	0.002
delta plus	AY.1	L452R, T478K, K417N	25.2	103000	0.0026
eta	B.1.525	E484K	18.7	160000	0.0029
lambda	C.37	L452Q, F490S	26.1	93300	0.00244
AD		N501Y, T478K	3.01	153000	0.000459

637  
638  
639  
640

## FIGURES LEGEND

641 **Fig. 1: Schematic of cpVNT workflow and results obtained with contrived whole-**  
642 **blood sample. A.** Graphical representation of the modified cpVNT workflow before  
643 detection in fluorescent reader. **B.** Cartoon depicting of possible molecular events  
644 occur in samples with and without nAb on the test spot and reagent control spot. **C.**  
645 Measurement of fluorescence intensity from pre vaccination whole blood samples  
646 titrated with 1, 5, 10, 25, 50, 100 nM SARS-CoV-2 monoclonal neutralizing antibody  
647 (nAb) **D.** The percent blocking calculated from Equation 1 with nAb concentration  
648 presented in log scale.

649  
650 **Fig. 2: Evaluation of nAb response among pre-vaccination and post-vaccinated**  
651 **individuals using modified cpVNT. A.** The percent blocking measured from 170  
652 whole blood samples of pre vaccination, Pre-Vac (n=36), post 1<sup>st</sup> dose (1-2W n=10,  
653 3-6W n=50) and post 2<sup>nd</sup> dose (n=74). The grey line is the median from each group



654 while each dot represents the mean from three independent experiments. **B.** The nAb  
655 percent blocking measured in individuals opt for BNT162b2 (n=4 from P1 - 1-2W, n=30  
656 from P1 - 3-6W, n=40 from P2) or **C.** mRNA-1273 (P1 - 1-2W n=6; P1 - 3-6W n=20;  
657 P2 n=34). Kruskal-Wallis test with Dunn's multiple comparison was performed  
658 between each vaccination status. **D.** Comparison of nAb percent blocking at P1 3-6W  
659 BNT162b2 and P1 3-6W mRNA-1273. Two tailed Mann-Whitney test was performed  
660 between the two vaccine brands. The significance values \*  $P < 0.05$ , \*\*  $P < 0.01$ , \*\*\*  $P$   
661  $< 0.001$ , \*\*\*\*  $P < 0.0001$ . Total samples: Pre-Vac versus P1 – 3-6W,  $P < 0.001$ ; Pre-  
662 Vac versus P2,  $P < 0.0001$ . BNT162b2: Pre-Vac versus P1 – 3-6W,  $P < 0.05$ ; Pre-Vac  
663 versus P2,  $P < 0.0001$ . mRNA-1273: Pre-Vac versus P1 – 3-6W,  $P < 0.001$ ; Pre-Vac  
664 versus P2,  $P < 0.0001$ . **E.** Twenty-two individual samples percent blocking mapped  
665 over pre and post vaccination period comparing between two types of vaccines,  
666 BNT162b2 n=12, mRNA 1273 n=10. The window period between first and second  
667 dose of vaccination ranged from 4 to 6 weeks depending on individual's choice.

668

669 **Fig. 3: Comparison of modified cpVNT with international standards and**  
670 **established serology tests.** **A.** The performance of the First WHO International  
671 standard Anti-SARS-CoV-2 Immunoglobulin (20/136), Reference Panel for anti-  
672 SARS-CoV-2 Mid-titre and Low-titre plasma using modified cpVNT. **B.** The correlation  
673 of percent blocking measured from 30 matching plasma and blood samples at pre  
674 vaccination (Pre-Vac), post 1<sup>st</sup> dose (P1) and post 2<sup>nd</sup> dose (P2) phase using modified  
675 cpVNT gave Pearson  $r$ , 0.908. The percent blocking for cpVNT with blood samples  
676 that correspond to 1000 IU/mL, 220 IU/mL and 44 IU/mL are determined by assuming  
677 a linear correlation between the two sample types (see accompanying table). **C.**  
678 Comparison of percent blocking measured in the modified cpVNT with percent  
679 inhibition of sVNT (cPass™) in 45 matching Pre-Vac, P1 and P2 venous blood and  
680 plasma samples. The sensitivity was calculated as 81.5% (CI: 61.9-93.7%), and  
681 specificity is 100% (CI: 81.5-100%) when both cpVNT and sVNT's (cPass™ )  
682 thresholds were set at 30% blocking. **D.** Comparison between cpVNT and pseudovirus  
683 neutralization test (pVNT) with 20 individuals' sample. The pVNT was performed with  
684 plasma in 1:80 dilution. The sensitivity is 100% (CI: 47.8-99.9%) and specificity is 66.7%  
685 (CI: 38.4-88.2%) with 30% blocking as the threshold for cpVNT and 50% neutralization  
686 for pVNT. All experiments were performed in triplicates.


687

688 **Fig. 4: Assessment of nAb response to variants of concern depending on**  
689 **vaccine brand or time post vaccination with our modified cpVNT. A.** Whole blood  
690 samples (n=39) from participants who completed vaccination within three months were  
691 tested with wildtype (WT) RBD-CBD and variant RBD-CBD. Friedman test with  
692 multiple comparison was performed comparing the variants against WT, \* $P < 0.05$ , \*\* $P$   
693  $< 0.01$ , \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$ . WT versus alpha,  $P < 0.01$ ; WT versus beta,  $P <$   
694  $0.0001$ ; WT versus gamma,  $P < 0.0001$ ; WT versus delta, n.s. **B.** The percent blocking  
695 of nAb measured from 20 P2 samples of BNT162b2 recipients ( $\leq 3$  months) when  
696 tested with RBD-CBD variants **C.** Similarly, percent nAb blocking of 19 P2 samples ( $\leq$   
697 3 months) from mRNA-1273 recipients tested with the RBD-CBD variants. **D.** The nAb  
698 response in BNT16b2 recipients against WT and RBD-CBD variants when comparing  
699 two groups: within three months (n=20) and more than three months (n=37) after  
700 complete vaccination. Two-sided Mann Whitney test was performed between the two  
701 groups for each variant, WT  $P < 0.0001$ , alpha  $P < 0.001$ , beta  $P < 0.0001$ , gamma  $P$   
702  $< 0.001$ , delta  $P < 0.0001$ .

703

704


**FIGURE 1**



**Schematic of cpVNT workflow and results obtained with contrived whole-blood sample.**

**A.** Graphical representation of the modified cpVNT workflow before detection in fluorescent reader. **B.** Cartoon depicting of possible molecular events occur in samples with and without nAb on the test spot and reagent control spot. **C.** Measurement of fluorescence intensity from pre vaccination whole blood samples titrated with 1, 5, 10, 25, 50, 100 nM SARS-CoV-2 monoclonal neutralizing antibody (nAb) **D.** The percent blocking calculated from Equation 1 with nAb concentration presented in log scale.


**FIGURE 2**



**Evaluation of nAb response among pre-vaccination and post-vaccinated individuals using modified cpVNT.**

**A.** The percent blocking measured from 170 whole blood samples of pre vaccination, Pre-Vac (n=36), post 1<sup>st</sup> dose (1-2W n=10, 3-6W n=50) and post 2<sup>nd</sup> dose (n=74). The grey line is the median from each group while each dot represents the mean from three independent experiments. **B.** The nAb percent blocking measured in individuals opt for BNT162b2 (n=4 from P1 - 1-2W, n=30 from P1 - 3-6W, n=40 from P2) or **C.** mRNA-1273 (P1 - 1-2W n=6, P1 - 3-6W n=20, P2 n=34). Kruskal-Wallis test with Dunn's multiple comparison was performed between each vaccination status. **D.** Comparison of nAb percent blocking at P1 3-6W BNT162b2 and P1 3-6W mRNA-1273. Two tailed Mann-Whitney test was performed between the two vaccine brands. The significance values \*  $P < 0.05$ , \*\*  $P < 0.01$ , \*\*\*  $P < 0.001$ , \*\*\*\*  $P < 0.0001$ . Total samples: Pre-Vac versus P1 - 3-6W,  $P < 0.001$ ; Pre-Vac versus P2,  $P < 0.0001$ . BNT162b2: Pre-Vac versus P1 - 3-6W,  $P < 0.05$ ; Pre-Vac versus P2,  $P < 0.0001$ . mRNA-1273: Pre-Vac versus P1 - 3-6W,  $P < 0.001$ ; Pre-Vac versus P2,  $P < 0.0001$ . **E.** Twenty-two individual samples percent blocking mapped over pre and post vaccination period comparing between two types of vaccines, BNT162b2 n=12, mRNA 1273 n=10. The window period between first and second dose of vaccination ranged from 4 to 6 weeks depending on individual's choice.


# FIGURE 3



## Comparison of modified cpVNT with international standards and established serology tests.

**A.** The performance of the First WHO International standard Anti-SARS-CoV-2 Immunoglobulin (20/136), Reference Panel for anti-SARS-CoV-2 Mid-titre and Low-titre plasma using modified cpVNT. **B.** The correlation of percent blocking measured from 30 matching plasma and blood samples at pre vaccination (Pre-Vac), post 1<sup>st</sup> dose (P1) and post 2<sup>nd</sup> dose (P2) phase using modified cpVNT gave Pearson  $r$ , 0.908. The percent blocking for cpVNT with blood samples that correspond to 1000 IU/mL, 220 IU/mL and 44 IU/mL are determined by assuming a linear correlation between the two sample types (see accompanying table). **C.** Comparison of percent blocking measured in the modified cpVNT with percent inhibition of sVNT (cPass<sup>TM</sup>) in 45 matching Pre-Vac, P1 and P2 venous blood and plasma samples. The sensitivity was calculated as 81.5% (CI: 61.9-93.7%), and specificity is 100% (CI: 81.5-100%) when both cpVNT and sVNT's (cPass<sup>TM</sup>) threshold were set at 30% blocking. **D.** Comparison between cpVNT and pseudovirus neutralization test (pVNT) with 20 individuals' sample. The pVNT was performed with plasma in 1:80 dilution. The sensitivity is 100% (CI: 47.8-99.9%) and specificity is 66.7% (CI: 38.4-88.2%) with 30% blocking as a threshold for cpVNT while 50% neutralization for pVNT. All experiments were performed in triplicates.

## FIGURE 4



### Assessment of nAb response to variants of concern depending on vaccine brand or time post vaccination with our modified cpVNT.

**A.** Whole blood samples ( $n=39$ ) from participants who completed vaccination within three months were tested with wildtype (WT) RBD-CBD and variant RBD-CBD. Friedman test with multiple comparison was performed comparing the variants against WT,  $*P < 0.05$ ,  $**P < 0.01$ ,  $***P < 0.001$ ,  $****P < 0.0001$ . WT versus alpha,  $P < 0.01$ ; WT versus beta,  $P < 0.0001$ ; WT versus gamma,  $P < 0.0001$ ; WT versus delta, n.s. **B.** The percent blocking of nAb measured from 20 P2 samples of BNT162b2 recipients ( $\leq 3$  months) when tested with RBD-CBD variants **C.** Similarly, percent nAb blocking of 19 P2 samples ( $\leq 3$  months) from mRNA-1273 recipients tested with the RBD-CBD variants **D.** The nAb response in BNT162b2 recipients against WT and RBD-CBD variants when comparing two groups: within three months ( $n=20$ ) and more than three months ( $n=37$ ) after complete vaccination. Two-sided Mann Whitney test was performed between the two groups for each variant, WT  $P < 0.0001$ , alpha  $P < 0.001$ , beta  $P < 0.0001$ , gamma  $P < 0.001$ , delta  $P < 0.0001$ .